DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers

We began analyzing https://link.springer.com/article/10.1007/s00280-003-0625-9, but it redirected us to https://link.springer.com/article/10.1007/s00280-003-0625-9. The analysis below is for the second page.

Title[redir]:
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside | Cancer Chemotherapy and Pharmacology
Description:
Thymidylate synthase (TS) is a folate-dependent enzyme that catalyzes the reductive methylation of 2′-deoxyuridine-5′-monophosphate to 2′-deoxythymidine-5′-monophosphate. This pathway provides the sole intracellular de novo source of 2′-deoxythymidine-5′-triphosphate; therefore, TS represents a critical target in cancer chemotherapy. 5-Fluorouracil (5-FU) was synthesized in 1957 and represents the first class of antineoplastic agents to be developed as inhibitors of TS. While 5-FU has been widely used to treat various human malignancies, its overall clinical efficacy is limited. Therefore, significant efforts have focused on the design of novel, more potent inhibitor compounds of TS. These agents fall into two main categories: folate analogs and nucleotide analogs. Five antifolate analogs are currently being evaluated in the clinic: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L. Our laboratory has identified a novel mechanism of resistance that develops to TS inhibitor compounds, namely drug-mediated acute induction of new TS synthesis; this mechanism is directly controlled at the translational level. The ability of cancer cells to acutely induce the expression of TS may represent a novel mechanism for the development of cellular drug resistance. The future success of TS inhibitor compounds in the clinic may depend on novel strategies to selectively inhibit TS and on novel combination therapies to overcome cellular drug resistance.

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 80,486,609 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure how the site profits.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

google, scholar, cancer, cas, pubmed, thymidylate, synthase, oncol, phase, article, clin, fluorouracil, patients, chu, inhibitor, advanced, res, allegra, proc, trial, colorectal, chemotherapy, study, protein, abstract, human, ann, anticancer, expression, smith, antifolate, resistance, johnston, maley, raltitrexed, usa, soc, suppl, binding, treatment, jackman, leichman, inhibitors, clinical, drug, acid, natl, carcinoma, activity, infusion,

Topics {✒️}

month download article/chapter small-cell lung cancer drug-mediated acute induction 4-dihydro-2-amino-6-methyl-4-oxo-5 o'dwyer pj molecular docking studies anti-cancer drug loaded wild-type p53 synthesis phase i-ii trial article cancer chemotherapy 5-fu-induced p53 expression quinazoline-based inhibitor full article pdf cellular drug resistance intravenous continuous infusion critical target human colon cancer privacy choices/manage cookies tumour response 5-fu-based chemotherapy related subjects human thymidylate synthase thymidylate synthase inhibitors human cell lines thymidylate synthase inhibitor oral folic acid thymidylate synthase gene 5-day continuous infusion thymidylate synthase mrna thymidylate synthase levels squamous cell carcinoma high-dose leucovorin randomized multicenter trial thymidylate synthase protein thymidylate synthase inhibition murine colon tumors tumor cell lines yale cancer center thymidylate synthase expression line therapy dihydrofolate reductase protein meta-analysis human p53 expression p53 mrna form dose-escalation study national cancer institute potent inhibitor compounds prevents translation initiation previously treated patients phase ii trial

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
         description:Thymidylate synthase (TS) is a folate-dependent enzyme that catalyzes the reductive methylation of 2′-deoxyuridine-5′-monophosphate to 2′-deoxythymidine-5′-monophosphate. This pathway provides the sole intracellular de novo source of 2′-deoxythymidine-5′-triphosphate; therefore, TS represents a critical target in cancer chemotherapy. 5-Fluorouracil (5-FU) was synthesized in 1957 and represents the first class of antineoplastic agents to be developed as inhibitors of TS. While 5-FU has been widely used to treat various human malignancies, its overall clinical efficacy is limited. Therefore, significant efforts have focused on the design of novel, more potent inhibitor compounds of TS. These agents fall into two main categories: folate analogs and nucleotide analogs. Five antifolate analogs are currently being evaluated in the clinic: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L. Our laboratory has identified a novel mechanism of resistance that develops to TS inhibitor compounds, namely drug-mediated acute induction of new TS synthesis; this mechanism is directly controlled at the translational level. The ability of cancer cells to acutely induce the expression of TS may represent a novel mechanism for the development of cellular drug resistance. The future success of TS inhibitor compounds in the clinic may depend on novel strategies to selectively inhibit TS and on novel combination therapies to overcome cellular drug resistance.
         datePublished:2003-06-18T00:00:00Z
         dateModified:2003-06-18T00:00:00Z
         pageStart:80
         pageEnd:89
         sameAs:https://doi.org/10.1007/s00280-003-0625-9
         keywords:
            Thymidylate synthase
            Cancer chemotherapy
            Drug resistance
            5-Fluorouracil
            Antifolates
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb1.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb2.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb3.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:52
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Edward Chu
               affiliation:
                     name:VA Connecticut Healthcare System
                     address:
                        name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Marc A. Callender
               affiliation:
                     name:VA Connecticut Healthcare System
                     address:
                        name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael P. Farrell
               affiliation:
                     name:VA Connecticut Healthcare System
                     address:
                        name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John C. Schmitz
               affiliation:
                     name:VA Connecticut Healthcare System
                     address:
                        name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
      description:Thymidylate synthase (TS) is a folate-dependent enzyme that catalyzes the reductive methylation of 2′-deoxyuridine-5′-monophosphate to 2′-deoxythymidine-5′-monophosphate. This pathway provides the sole intracellular de novo source of 2′-deoxythymidine-5′-triphosphate; therefore, TS represents a critical target in cancer chemotherapy. 5-Fluorouracil (5-FU) was synthesized in 1957 and represents the first class of antineoplastic agents to be developed as inhibitors of TS. While 5-FU has been widely used to treat various human malignancies, its overall clinical efficacy is limited. Therefore, significant efforts have focused on the design of novel, more potent inhibitor compounds of TS. These agents fall into two main categories: folate analogs and nucleotide analogs. Five antifolate analogs are currently being evaluated in the clinic: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L. Our laboratory has identified a novel mechanism of resistance that develops to TS inhibitor compounds, namely drug-mediated acute induction of new TS synthesis; this mechanism is directly controlled at the translational level. The ability of cancer cells to acutely induce the expression of TS may represent a novel mechanism for the development of cellular drug resistance. The future success of TS inhibitor compounds in the clinic may depend on novel strategies to selectively inhibit TS and on novel combination therapies to overcome cellular drug resistance.
      datePublished:2003-06-18T00:00:00Z
      dateModified:2003-06-18T00:00:00Z
      pageStart:80
      pageEnd:89
      sameAs:https://doi.org/10.1007/s00280-003-0625-9
      keywords:
         Thymidylate synthase
         Cancer chemotherapy
         Drug resistance
         5-Fluorouracil
         Antifolates
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb1.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb2.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-003-0625-9/MediaObjects/s00280-003-0625-9flb3.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:52
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Edward Chu
            affiliation:
                  name:VA Connecticut Healthcare System
                  address:
                     name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Marc A. Callender
            affiliation:
                  name:VA Connecticut Healthcare System
                  address:
                     name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael P. Farrell
            affiliation:
                  name:VA Connecticut Healthcare System
                  address:
                     name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John C. Schmitz
            affiliation:
                  name:VA Connecticut Healthcare System
                  address:
                     name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:52
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:VA Connecticut Healthcare System
      address:
         name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:VA Connecticut Healthcare System
      address:
         name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:VA Connecticut Healthcare System
      address:
         name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:VA Connecticut Healthcare System
      address:
         name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Edward Chu
      affiliation:
            name:VA Connecticut Healthcare System
            address:
               name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Marc A. Callender
      affiliation:
            name:VA Connecticut Healthcare System
            address:
               name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Michael P. Farrell
      affiliation:
            name:VA Connecticut Healthcare System
            address:
               name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:John C. Schmitz
      affiliation:
            name:VA Connecticut Healthcare System
            address:
               name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
      name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
      name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
      name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
      name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
      name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
      name:Cancer Center – 111D, VA Connecticut Healthcare System, West Haven, USA
      name:Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(274)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

5s.